Checkmate Pharmaceuticals Inc


Checkmate Pharmaceuticals Inc

  • Price (USD)6.15
  • Today's Change-0.12 / -1.91%
  • Shares traded40.15k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 17 2021 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing its technology to harness the power of the immune system to combat cancer. Its product candidate, CMP-001, is a differentiated Toll-like receptor 9 (TLR9), agonist delivered as a biologic virus-like particle (VLP), utilizing a CpG-A oligonucleotide as a key component. When injected into a tumor, CMP-001 is designed to trigger the body’s innate immune system, thereby altering the tumor microenvironment and directing activated anti-tumor T cells to attack both the injected tumor and also tumors throughout the body. The Company is also developing CMP-001 in combination with several checkpoint inhibitor immunotherapies in melanoma and head and neck cancer.

  • Revenue in USD (TTM)0.00
  • Net income in USD-47.44m
  • Incorporated2015
  • Employees25.00
  • Location
    Checkmate Pharmaceuticals Inc245 Main Street, 2Nd FloorCAMBRIDGE 02142United StatesUSA
  • Phone+1 (978) 503-2124
  • Fax+1 (302) 655-5049
  • Websitehttp://checkmatepharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Aptevo Therapeutics Inc6.73m-28.59m131.13m58.00--12.48--19.48-7.85-7.671.832.360.1432----116,034.50-60.84-66.64-99.17-90.59-----424.84-538.61----0.5846-----33.6928.19---43.49--
Yumanity Therapeutics Inc10.43m-49.59m134.67m46.00--2.75--12.91-18.64-18.642.354.800.1261----237,000.00-68.08-60.13-81.16-68.85-----539.81-966.61---20.700.2374--37.929.8514.10---1.33--
Checkmate Pharmaceuticals Inc0.00-47.44m135.59m25.00--1.21-----2.20-
Catalyst Biosciences Inc6.05m-74.63m135.74m36.00--1.30--22.44-3.34-3.340.26753.320.0527--5.10168,027.80-64.99-46.96-73.30-61.83-1.90---1,233.69-804.52----0.00----64.29-1.93---0.3704--
Concert Pharmaceuticals Inc7.90m-76.96m136.10m71.00--1.19--17.23-2.37-2.370.24393.540.0483--197.50111,267.60-47.03-20.63-50.52-21.91-----974.15-100.30----0.00--633.70-34.734.35---24.71--
OncoSec Medical Inc0.00-42.34m136.36m42.00--2.85-----1.51-1.510.001.220.00----0.00-82.40-113.86-98.07-137.28------------0.00-------39.56------
LogicBio Therapeutics Inc2.89m-33.45m136.68m39.00--2.51--47.23-1.24-1.240.1051.690.0472----74,205.13-54.53---60.93-------1,155.77-----29.880.1567------18.71------
Imara Inc0.00-44.40m137.24m27.00--1.81-----2.55-2.550.004.290.00----0.00-46.25---48.91--------------0.00-------109.77------
Otonomy Inc203.00k-45.18m137.58m56.00--2.10--677.74-1.03-1.030.00441.160.0025----3,625.00-55.28-50.47-63.93-54.91-345.32-111.93-22,255.17-9,626.447.14-30.830.2134---54.50---0.1254---41.87--
Liquidia Corp3.82m-54.15m137.73m51.00--1.83--36.02-1.49-1.490.10161.450.0541----74,965.88-76.69---92.36--75.64---1,416.45-----62.420.1499---90.84---25.60------
Rayont Inc1.60m330.00k137.89m--275.3635.59287.2486.390.01060.01060.05370.08160.5022--3.64--10.38-66.7913.85-172.8661.3213.6220.67-146.810.627-14.900.1829-----23.9190.03------
Eyenovia Inc4.00m-19.67m138.07m31.00--11.27--34.52-0.8634-0.86340.17360.47380.1828--6.32129,032.30-89.90-107.55-158.27-145.7760.00---491.77-3,342.16---1,362.870.0825------6.56--120.87--
Odonate Therapeutics Inc0.00-129.96m139.40m137.00--1.32-----3.79-3.790.002.730.00----0.00-85.25-58.36-105.34-65.14------------0.00-------12.99------
Biomx Inc0.00-32.59m139.88m95.00--2.58-----1.40-1.400.002.230.00----0.00-43.01---46.67--------------0.00-------46.31------
Data as of Jun 17 2021. Currency figures normalised to Checkmate Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

17.50%Per cent of shares held by top holders
HolderShares% Held
Clough Capital Partners LPas of 07 May 20211.55m7.18%
Sectoral Asset Management, Inc.as of 31 Mar 2021541.77k2.51%
DNCA Finance SAas of 31 Dec 2020505.29k2.34%
The Vanguard Group, Inc.as of 31 Mar 2021360.71k1.67%
BlackRock Fund Advisorsas of 31 Mar 2021303.44k1.40%
DWS Investment GmbHas of 31 Mar 2021132.32k0.61%
Ensign Peak Advisors, Inc.as of 31 Mar 2021119.92k0.55%
Geode Capital Management LLCas of 31 Mar 2021103.43k0.48%
SSgA Funds Management, Inc.as of 31 Mar 202183.26k0.39%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202181.36k0.38%
More ▼
Data from 26 Feb 2021 - 31 Mar 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.